Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Uninsured shoppers are the most exposed, because there is no insurance billing department to catch a duplicate charge
How Retatrutide Compares to Existing Therapies The progression from single to dual to triple agonist therapy represents a clear trend in obesity pharmacotherapy: Semaglutide (GLP-1 agonist): ~1517% weight loss in Phase III (STEP trials) Tirzepatide (GIP + GLP-1 dual agonist): ~2022.5% weight loss in Phase III (SURMOUNT trials) Retatrutide (GIP + GLP-1 + glucagon triple agonist): ~2629% weight loss in Phase III (TRIUMPH-4) Each additional receptor pathway appears to contribute incremental efficacy
Conversion charts between semaglutide and tirzepatide exist to help guide these transitions
Individuals who fall within one of those three weight classifications are at an increased risk of developing significant health problems, increasing their risk of developing: Various Types of Cancer, Diabetes, and Heart Disease (e.g., heart attack, stroke, etc.)
10mg vial Growth hormone-releasing factor analog for visceral fat research
Hope DCD, Tan TMM
US$ 27.60
US$ 24.64
US$ 25.46
US$ 21.14
US$ 21.48
US$ 27.87
US$ 29.00
